02/20/2022

ESTIMATING THE EFFECT OF VACCINATION ON THE CASE-FATALITY RATE FOR COVID-19

Glen H. Murata, MD*

Allison E. Murata, MSIM^

Douglas J. Perkins, PhD[#]

Curt H. Hagedorn, MD*[#]

Brent Wagner, MD*[#]

Heather M. Campbell, PharmD, PhD^{^&}

Benjamin H. McMahon, PhD[%]

Jenny T. Mao, MD, FCCP*[#]

* New Mexico VA Health Care System, Albuquerque NM

^ VA Cooperative Studies Program - Clinical Research Pharmacy Coordinating Center,
Albuquerque NM

[#] University of New Mexico School of Medicine, Albuquerque NM

[&] University of New Mexico College of Pharmacy, Albuquerque NM

[%] Los Alamos National Laboratory, Los Alamos NM

COVID VACCINATION AND CASE FATALITY RATE

2

ABSTRACT

Objective: To evaluate the effectiveness of vaccination on the case fatality rate (CFR) for COVID-19 infection. Unlike infection or mortality rates, CFR is not affected by unmeasured patient behaviors or environmental factors that affect the risk of exposure.

Methods: Cases were identified through the COVID Shared Data Resource (CSDR) of the Department of Veterans Affairs. Patients were included in this study if they had baseline data available for risk stratification. The primary outcome was death within 60 days of the first positive nucleic acid amplification test (NAAT). A patient was considered fully vaccinated if they had received one dose of the Johnson & Johnson product or two doses of any other formulation, at least, 14 days prior to the NAAT. Cases diagnosed in July, August, or September of 2021 were considered to have the delta variant. We used novel methods to control for confounders in multiple domains of the electronic medical record, including ICD10 codes, vital signs, baseline laboratory tests and outpatient medications. These procedures included retrieving all entries more than 14 days prior to the NAAT; deriving summary measures of their contribution to the risk of death; and including these measures as covariates in a logistic regression model evaluating vaccine effectiveness. PDeathDx refers to the risk of death based on 153 root ICD10 codes previously shown to be independent predictors of mortality. PDeathLabs refers to the risk based on 49 parameters from 4 vital signs and 7 baseline laboratory tests. AggRiskDx refers to the aggregate effect of 8 drug classes shown to have protective effects. Other predictors in the model included demographic characteristics and comorbidity scores. Logistic regression was used to derive adjusted odds ratios for the vaccination and delta terms. Separate models were developed for early COVID variants and the delta variant. Split sample validation was used to determine if the estimates for vaccine and delta effects were stable across independent patient samples. Patients with a delta infection were divided into 8 cohorts based upon the time from vaccination to diagnosis (in 4-week

COVID VACCINATION AND CASE FATALITY RATE

3

blocks). A model for COVID death was fitted to the data from each cohort to obtain cohort-specific adjusted odds ratios for vaccination.

Results: On September 30, 2021, there were 339,772 patients in the COVID CSDR who met the criteria for this study. 9.1% had been fully vaccinated, while 21.5% were presumed to have the delta variant. The median time from vaccination to diagnosis was 154 days. Overall, 18,120 patients (5.33%) died within 60 days of their diagnosis. Multivariate modeling showed that age, gender, race, ethnicity, veteran status, PDeathDx, PDeathLabs, AggRiskRx and 3 of 4 comorbidity measures were independent risk factors for death within 60 days. The adjusted odds ratio for delta infection was 1.87 ± 0.05 , which corresponds to a relative risk of 1.78. The adjusted odds ratio for prior vaccination was 0.280 ± 0.011 , corresponding to a relative risk of 0.291. Separate models showed that vaccination had even greater benefits for delta infections than for earlier variants. Split sample procedures showed that the estimates for vaccine and delta effects were stable across independent samples. The study of vaccine cohorts showed that the benefits of vaccination peaked at 10-14 weeks and remained stable for 30-34 weeks.

Conclusions: Estimates of vaccine effectiveness are valid to the extent that they exclude non-vaccine effects and control for confounders. Infection and mortality rates depend upon the risk of exposure which, in turn, depends upon the extent to which the patient adheres to COVID precautions and environmental factors. Moreover, there are hundreds of confounders that may promote higher vaccination rates in those suspected to have poor outcomes if they contract the virus. Our study used CFR and novel procedures to mitigate these problems. Although delta is substantially more lethal than earlier variants, vaccination reduces the risk of death by over 70%. Moreover, the benefit of such was observed at a median of 5 months after vaccination. We found no evidence that the effectiveness of COVID vaccination declined over time. Our study using CFR confirms that vaccination is an effective means of preventing COVID death and suggests that CFR would better identify changes in virulence of new variants.

INTRODUCTION

Recent studies have shown an alarming decrease in the effectiveness of COVID vaccines over time (1-3). The metrics for effectiveness included infection and mortality rates (4, 5). It is imperative that we understand the mechanisms by which vaccines begin to fail. Such efforts can be facilitated by a robust framework for classifying vaccine effects. The most straightforward method is to use a probabilistic approach. Patients who succumb to a contagious disease must first be exposed, then develop an infection as a result of the exposure, and then die as a consequence of the infection. The risk of death in a population observed for a given time is thus the joint probability of these 3 events or $P(\text{exposure, infection, death})$. From the multiplicative rule of probability theory:

$$P(\text{exposure, disease, death}) = P(\text{exposure}) * P(\text{infection} | \text{exposure}) * P(\text{death} | \text{exposure, disease})$$

Likewise, the risk of infection is the joint probability of the first 2:

$$P(\text{exposure, disease}) = P(\text{exposure}) * P(\text{infection} | \text{exposure})$$

It is important to separate these metrics into their underlying risks because the latter represent separate targets for interventions. For example, COVID precautions focus on $P(\text{exposure})$, while anti-virals target $P(\text{death} | \text{exposure, disease})$. Vaccination has favorable effects on $P(\text{infection} | \text{exposure})$ and $P(\text{death} | \text{exposure, disease})$ by promoting an immune response. It will hopefully decrease $P(\text{exposure})$ when herd immunity is achieved. Thus, vaccine effectiveness might vary depending upon which risk is targeted. Moreover, changes in one risk may be offset by changes in another - leading to erroneous conclusions about vaccine effectiveness. For example, beneficial effects of the vaccine on $P(\text{infection} | \text{exposure})$ may be diminished by abandoning COVID precautions which increases $P(\text{exposure})$.

One problem with certain models for vaccine effectiveness is that they do not account for the risk of exposure. Doing so requires adjustments for patient behaviors and community level effects. The former include adherence to COVID precautions such as masking, social distancing, handwashing, avoidance of large crowds, testing of contacts, and working from

COVID VACCINATION AND CASE FATALITY RATE

5

home. The latter include the prevalence of the virus, its infectivity, the extent to which the community embraces COVID precautions, and government mandates. As a result, increases in infection and mortality rates may be related to diminished vaccine effectiveness, changes in exposures, or both. In this study, we focused on the third risk or $P(\text{death} \mid \text{exposure, disease})$. This term is analogous to the case fatality rate (CFR). We have chosen this outcome to assess vaccine effectiveness because, unlike infection and mortality rates, it is not affected by unmeasured patient behaviors and environmental factors.

Measuring effectiveness in observational studies requires a robust approach because treatment is not randomly allocated across a population. Confounding is introduced when the treatment (vaccination) affects the outcome, the condition for which treatment is indicated (a pre-existing condition) affects the outcome, and there is an association between the severity of the condition and the likelihood of treatment. The latter can be positively or negatively correlated, in which case treatment effects are under- or overestimated, respectively. In most cases, the benefits of treatment are offset by their preferential use in patients with a poorer prognosis. As such, the benefit can only be revealed when the bias is removed by multivariate analysis which separates the independent effects of treatment and associated comorbidities. The biggest challenge is that there are hundreds of conditions that may serve as confounders. Co-morbidity scores may not be suitable for this purpose because they do not represent all of the conditions that may be high risk. Thus, a patient with an included condition of moderate risk may be given a higher score than another with a rare condition that is fatal. Critical findings on vital signs and laboratory tests may also serve as confounders. The most robust solution is to do a systematic survey of all high-risk conditions from several domains in the medical record and adjust the effect of vaccination by some aggregate measure of their effect. We have developed such procedures for individual ICD10 codes, vital signs, commonly used laboratory tests, and outpatient medications. As a result, our estimates of vaccine effect on the case fatality rate may be one of the least biased approaches of those reported to date.

METHODS

Cases were identified through VA's COVID Shared Data Resource (CSDR). Membership in this registry requires at least one positive nucleic acid amplification test. Subjects were included in this study if their index infections occurred before October 2021. Delta variants of the virus were considered the infecting agent for those presenting in July, August, or September of 2021. Although sporadic cases of delta were reported in late May, delta was the predominant variant over the time we selected. The primary outcome was death within 60 days of the diagnosis. The outcome was retrieved from the CSDR, which assigns a 1 to those who died and 0 otherwise. The cohort was followed through November 2021 so that each subject reached a definitive endpoint.

VA maintains two databases containing information on COVID vaccination. CSDR has a robust and highly vetted registry of patients who have been vaccinated within and outside of the agency. The immunization domain of the Corporate Data Warehouse (CDW) contains similar information but is less structured and contains duplicates. The CDW data were scrubbed and re-organized to match the CSDR format. Cases identified in CDW, but not in CSDR, were added to the latter to create a pooled vaccine registry. Patients were considered vaccinated if they had received 1 dose of the Johnson & Johnson product or 2 doses of any other formulation at least 14 days prior to the diagnosis of COVID.

PDeathDx refers to the predicted probability of death based upon 153 ICD10 root diagnoses (6). Pre-existing conditions were identified by reviewing all diagnoses entered into the electronic medical record during outpatient visits, as updates to the patient problem list, or at the time of hospital discharge. "Pre-existing" refers to entries made up to 14 days prior to the COVID diagnosis. ICD9 codes were converted to ICD10 using a crosswalk provided by the Centers for Medicare/ Medicaid Services. A "root diagnosis" was defined as all characters preceding the decimal point for ICD10 codes or the ICD9 equivalent. Each patient was deemed to have (or not have) each root condition. A proprietary computer program was used to identify

COVID VACCINATION AND CASE FATALITY RATE

7

all patients with a given condition who died or survived, as well as all patients without the condition who died or survived. The software used these cell frequencies to derive the relative risk (RR) of death associated with the condition along with the confidence interval (CI). CIs were adjusted for multiple comparisons by the Bonferroni method. A root diagnosis was considered to have a significant effect on the outcome if the lower limit for the CI was ≥ 1.5 or the upper limit for the CI was ≤ 0.80 . The procedure was thus used to identify conditions that were either high-risk or protective. Stepwise logistic regression identified those diagnoses that were independent predictors of death. The model was then used to generate a predicted probability of death (PDeathDx) for each subject.

PDeathLabs refers to the predicted probability of death based upon 49 parameters derived from complete value sets for 4 vital signs (systolic blood pressure, diastolic blood pressure, O2 saturation, and body mass index) and 7 routine laboratory tests (estimated glomerular filtration rate, ALT, hematocrit, serum albumin, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and hemoglobin A1c) (7). Entries for these 11 clinical measurements were retrieved if their recorded dates were ≥ 14 days prior to the diagnosis of COVID. 13 parameters were derived for each type of measurement to reflect criteria used by practitioners to assess metabolic control (total = $13 * 11 = 143$). Logistic modeling showed that 49 of these parameters were independently predictive of death (Murata GH, doi pending). The model was used to assign a predicted probability of death (PDeathLabs) based on clinical measurements to each subject.

Current treatment was identified by reviewing all outpatient medications active on the 14th day prior to the COVID diagnosis. A patient was considered on treatment if (s)he still had a supply of medications from their most recent “fill” on the cutoff date. The VA system assigns each formulation to one or more drug classes. A process identical to the one above was used to assign a RR and CI to each of the 343 VA drug classes. AggRiskRx refers to the protective effect of 8 VA drug classes with an upper boundary for CI ≤ 0.80 . This definition presumes that

a protective effect goes beyond neutralizing the underlying condition and is therefore likely to be independent of its initial indication. An aggregate effect for all 8 classes was derived by log transforming the relative risk for each and adding the transformed values. This approach assumes that their effect was independent and that the aggregate effect was the product of the individual RR. We did not examine high-risk drugs because the RR of pre-existing conditions reflects the underlying disease as well as the drugs used to treat the condition.

Age at diagnosis, gender, self-reported race and ethnicity, veteran status, smoking history and use of supplemental oxygen were retrieved from the CSDR. The CSDR was also interrogated for the 2-year (Charl2Yrs) and lifetime Charlson Comorbidity Index (CharlEver) and the 2-year (Elix2Yrs) and lifetime Elixhauser (ElixEver) scores.

Statistical methods – Univariate analysis was used to compare the attributes of patients who died and survived. Group differences in nominal variables were tested by chi-square analysis. Group differences in continuous variables were examined by the student's t-test or Mann-Whitney U-test.

Main model - Stepwise logistic regression was used to construct a multivariate model for COVID death in the entire sample. The dependent variable was death within 60 days of the diagnosis. The predictor of interest was prior vaccination for COVID-19. Covariates included age, gender, race, ethnicity, veteran status, current smoking, use of supplemental oxygen, PDeathDx, PDeathLabs, AggRiskRx, Charl2Yrs, CharlEver, Elix2Yrs, ElixEver and delta variant virus infection. Variables were entered in a stepwise fashion with a P-to-enter of 0.01 and to remove of 0.05. The model was used to derive an overall predicted probability of death (PDeath) for each patient. The ability of PDeath to discriminate between the two groups was assessed by the area under its receiver operator characteristic (ROC) curve. An adjusted odds ratio (OR) and its 95% CI was derived for the vaccination term. A standard on-line calculator was used to convert the adjusted OR to an equivalent RR. The identical procedure was used to evaluate the delta term.

Early variants versus delta – Separate models were developed for early variants (pre-July) and for delta (July - September) using the methods described above. The objective was to determine if predictors of death had changed significantly and if the effectiveness of prior vaccination differed for the two groups.

Split-sample validation – The purpose of this analysis was to determine if the estimates for vaccine and delta virus effects were stable across independent samples. Recall that our models retrospectively test the effect of vaccination, while controlling for as many confounders as possible. They were not designed as prediction models and not intended for use in future patients. Nevertheless, it is important to show that they perform well in different subsets and over time. A computer-generated random number was assigned to each subject. Patients with values ≤ 0.6 were assigned to a derivation set, while the remainder were assigned to a validation set. The model was re-derived for the derivation set. The predictors of the model were fitted to the validation sample to determine if the predictors remained significant. The derivation model was also used to assign a PDeath to each member of the validation set. The area under its ROC curve was used to assess discriminating power. Patients in the validation set were assigned to deciles of risk based upon PDeath. Chi-square analysis was used to determine if the frequency of observed cases varied across the deciles of risk.

Vaccine cohorts – Eight patient cohorts infected with delta were assembled based upon the time from vaccination to the date of diagnosis (VxToDx). Each cohort was comprised of patients whose VxToDx fell within a 4-week interval. Cohort 1 was vaccinated ≥ 2 and < 6 weeks prior to diagnosis, while Cohort 8 was vaccinated ≥ 30 and < 34 weeks earlier. Patients vaccinated ≥ 34 weeks prior to diagnosis were excluded because the subsequent cohorts were small. CFR was calculated for each cohort and plotted against cohort number (Figure 1).

Logistic modeling was used to derive cohort-specific adjusted odds ratios for vaccination. For cohort 1, patients in cohorts 2-8 were excluded from the data set of all delta patients. A common logistic model was then fitted to the remaining cases. This model was comprised of

vaccination status, age at diagnosis, male gender, use of supplemental oxygen, current smoking, prior vaccination, PDeathDx, PDeathLabs, Charl2Yrs, and CharlEver. This model was chosen because preliminary regressions showed that all variables were significant predictors of death for every cohort. The subset models also had similar power to discriminate between non-survivors and survivors (ROC areas from 0.810 to 0.816). The odds ratio for vaccination was therefore adjusted for 8 other demographic and clinical variables. This process was repeated for the remaining cohorts. The adjusted odds ratios for vaccination were plotted against cohort number (Figure 2).

RESULTS

On September 30, 2021, there were 347,220 COVID patients in VA's COVID Shared Data Resource. 339,772 (or 97.9%) had at least one pre-existing condition and form the basis for this report. The mean age at the time of diagnosis was 58.6 ± 16.7 years; 84.1% were male; 22.9% were members of a racial minority; 9.0% were Hispanic; 95.8% were veterans; 0.7% were on supplemental oxygen; and 11.8% were current smokers. 9.1% had been fully vaccinated at least 14 days prior to the COVID diagnosis. The median interval between vaccination and diagnosis was 154 days (interquartile range 111 to 185). 21.5% acquired their infections after July 1, 2021 and were presumed to have the delta variant. Overall, 18,120 patients (5.33%) died within 60 days of their diagnosis.

Table 1 shows the results of univariate analysis comparing non-survivors and survivors. Non-survivors were older and more likely to be male, white, and on supplemental oxygen but less likely to be Hispanic or current smokers. Vaccinated patients were less likely to die than the unvaccinated (3.95% vs 5.47%, respectively; $P < 0.001$). The case fatality rate was lower for those acquiring delta than earlier variants (4.64% vs 5.52%; $P < 0.001$). This finding persisted even when vaccinated patients were removed from the analysis (5.06% vs 5.55%; $P < 0.001$).

The main multivariate model is shown in **Table 2**. 239,393 patients (70.5%) had complete data sets available for multivariate modeling. 13 variables were identified as statistically significant and independent determinants of death at 60 days. A poorer prognosis was observed for the elderly, males, and Hispanics while being white was protective. PDeathDx, PDeathLabs, AggRiskRx, and 3 of 4 comorbidity measures were all significant predictors of death. The adjusted odds ratio for delta infection was 1.87 ± 0.05 which corresponds to a relative risk of 1.78. The adjusted odds ratio for prior vaccination was 0.280 ± 0.011 which corresponds to a relative risk of 0.291. This observation suggests that the delta variant is substantially more lethal than earlier variants – an effect that is largely offset by prior vaccination.

Tables 3 and 4 show the multivariate models for early COVID variants and delta, respectively. Of 11 variables identified as predictors before July 1, 2021, 8 were still significant after the emergence of delta. The adjusted odds ratio for vaccination prior to July 2021 was 0.404 ± 0.033 while the odds ratio thereafter was 0.259 ± 0.012 . The relative risk of death from delta associated with vaccination was 0.269 which corresponds to an effectiveness of 73.1%. This observation suggests that prior vaccination was more effective in reducing the case fatality rate for delta than earlier variants. However, only 4,649 (or 15.1%) of 18,120 breakthrough infections occurred before July 1. The earlier odds ratios were therefore based on a relatively small number of deaths in the vaccinated group.

Table 5 presents the model re-derived on a derivation set and then applied to a validation set (**Table 6**). The objective was to determine if the estimates of vaccine and delta effects were stable across independent samples. 13 variables were identified as significant predictors of death in the derivation set. 12 remained significant in the validation set while the last (Native American ancestry) showed a trend towards significance. Although not designed as a prediction model, the ROC area under the curve in the validation set was 0.826 - demonstrating

that the model was able to differentiate between dying and surviving patients in an independent sample.

Table 7 shows the observed versus predicted probability of death in the validation set over deciles of predicted risk. There is a reasonable correlation between expected and observed rates for predicted probabilities < 0.5 . Above that point, the predicted risk exceeds the observed in the small number so classified. 16,955 validation patients (17.9%) had a predicted probability of death ≥ 0.1 . The CFR in this group was 20.9%. There were only minor differences in the adjusted odds ratios for prior vaccination (0.284 ± 0.014 versus 0.275 ± 0.017) and for a delta infection (1.86 ± 0.06 versus 1.88 ± 0.08) between the two samples.

73,117 patients were presumed to have been infected with the delta variant. 26,168 (35.8%) had previously been vaccinated. 25,818 vaccinees were assigned to 8 cohorts defined by the time from completed vaccination to diagnosis (VxToDx) (in 4-week blocks). Cohort 1 was comprised of the most recent vaccinees while cohort 8 had the most remote vaccinations. The cohorts varied in size from 457 to 6,896 subjects. **Figure 1** shows that CFR fell across the lowest cohorts and reached a nadir of 2.19% for cohort 3. It then increased monotonically across cohorts 4 to 8. One possibility for the latter trend is that vaccine effectiveness declined after 10-14 weeks. However, patients in the highest cohorts also received their vaccinations the earliest after vaccines became available in the VA. The COVID-19 Vaccination Plan for the Veterans Health Administration acknowledged that elderly patients, certain ethnic groups, and those with major comorbidities were at high risk of death or complications. It also authorized a population-based risk stratification plan for vaccine administration and its implementation when supplies were limited. The earliest vaccinations were also driven by patient choice, provider concerns for underlying medical conditions, and residence in high-risk facilities. Thus, the high CFR in later cohorts may have been the result of a selection bias. For this reason, we developed a multivariate model for COVID death addressing the benefits of vaccination for each cohort. 52,613 patients (72.0% of all delta cases) were available for this analysis. For each

cohort of interest, patients in the other cohorts were excluded and a common model fitted to the remaining cases. The odds ratios for vaccination were adjusted for 8 other patient attributes.

Figure 2 shows that the adjusted odds ratio for vaccination declined across the lowest cohorts and remained low for remaining ones. Patients with the most remote vaccinations still had an adjusted odds ratio for vaccination of 0.244 ± 0.012 . Thus, there was no evidence that the vaccine effect on CFR declined over the observation period in this study.

DISCUSSION

In this paper, we stress the importance of a robust system for classifying vaccine effects. The reason is that the usual methods for evaluating effectiveness are composite measures reflecting 3 underlying risks (exposure, infection, death) and may not precisely define the mechanisms by which vaccines have failed. For example, the mortality rate is a function of the probabilities of exposure, developing an infection once exposed, and dying once infected. Improvements in the last 2 risks (i.e., for infection and death) may be offset by increases in the first (i.e., exposure) as patients abandon COVID precautions. On the other hand, CFR (case fatality rate) is a function of only the risk of death once infected. In this study, we determine the extent to which vaccination provides protection against mortality using a metric not affected by masking, social distancing, handwashing, early testing, and quarantines.

Observational studies of vaccine effectiveness are heavily biased. Patients at the highest risk of death are more likely to receive the vaccine for several reasons including personal choice, concern of their physicians, and/or national policies driven by vaccine shortages and stressed delivery systems. This prioritization confounds the relationship between the intervention and outcome because the benefits of vaccination are offset by their preferential use in patients with the poorest prognosis. The accuracy of estimates for vaccine effect depends upon the extent to which this bias is removed. Our study is unique in that we performed a systematic review of major domains in the medical record, identified observations associated with a poor outcome, and used summary measures of the findings to adjust the effects of

COVID VACCINATION AND CASE FATALITY RATE

14

vaccination. The review included clinical measurements that were not tested as candidate variables in other models but are critical determinants of survival (such as oxygen saturation). This approach is innovative because it represents intensive computer processing of hundreds of millions of observations to identify hundreds of potential confounders. While not perfect, our estimate of vaccine effect likely represents the most accurate metric reported to date.

We found that the adjusted odds ratio for vaccination was 0.280. This value corresponds to a 71% reduction in the risk of death. This benefit was observed at a median of 5.1 months after vaccination. Substantial benefits of vaccination were observed before and after the emergence of delta, although the former was significantly less. A validation study showed that the components of the original model were still significant in an independent sample, that it retained its ability to differentiate between those who died or survived, and that the estimate of vaccine effect remained stable.

Our cohort studies showed that CFR for vaccinees declined with time to a nadir 10-14 weeks after vaccination and then rose thereafter. Since CFR is not affected by patient behaviors or environmental factors, this pattern is consistent with the acquisition and subsequent loss of a physiological factor that promoted recovery from an established infection. The other possibility is a strong selection bias. Patients with the longest time from vaccination to diagnosis received their vaccines the earliest. For example, for delta infections acquired in August 2021, cohort 8 contained the very first vaccinees while cohort 1 contained patients who deferred their vaccinations until July. Because early vaccinations were directed at those at highest risk of death, CFR would be higher for early vaccinees regardless of vaccine effect. One population targeted for early vaccination was nursing home patients. This group could have had a higher CFR because they had more intense exposure to COVID-19, more advanced comorbidities, greater physical disability, and higher risk for lethal complications such as nosocomial superinfections. It would have been difficult to determine which patients were in private nursing homes whether under contract through the VA or through other arrangements.

On the other hand, cohort 1 may have deferred their vaccinations because they had a favorable perception of their own health. We developed cohort-specific measures of vaccine effectiveness because they differed in ways that had a profound effect on outcomes but could not be measured. Our results showed that the rising CFR with time was due to selection bias and not loss of vaccine effect. The benefits of vaccination remained large even at 30-34 weeks – the longest observation period in this study. This finding contrasts sharply with prior studies (1-3) showing a loss of vaccine effect over time. The difference may be the use of CFR instead of infection or mortality rates, more robust handling of confounders, and avoidance of selection biases introduced by the way that VA rolled out its vaccination program. Unlike infection or mortality rates, CFR is not affected by unmeasured personal behaviors or environmental factors that affect the probability of exposure. The odds ratios for vaccination in our models were also adjusted for a much larger number of pre-existing conditions, vital sign abnormalities, laboratory results, and medications than previously reported. Finally, because our cohorts were assembled over a short-time frame, our approach was not affected by VA's changing priorities for vaccination.

We do not have an explanation for why it took 10-14 weeks for vaccination to reach its maximal effect. Future studies should be done on the mechanisms by which COVID vaccination produces such late effects. Regardless of the reasons, our study suggests that COVID precautions should be observed for several weeks after vaccination until the full benefits are attained.

Prior vaccination has been included in other prediction models for COVID mortality. For example, Hippisley-Cox et al (8) published a multivariate model for COVID death in a large, vaccinated cohort in England. The investigators found that the adjusted hazard ratio for full versus partial vaccination was 0.17 (0.13 to 0.22), suggesting a major effect. Differences in vaccine effectiveness between our study and theirs may be explained by the populations studied. To be eligible for military service (and thus inclusion in the present study), individuals

COVID VACCINATION AND CASE FATALITY RATE

16

cannot have a debilitating congenital abnormality. It is also possible that veterans may have diminished immune responses to vaccination that may not be fully explained by covariates even in a highly specified model. The effect of vaccination on the case fatality rate may therefore depend upon the population studied.

Our definition of a delta infection relied on information provided by the Centers for Disease Control (CDC). CDC identifies and tracks COVID variants through genomic surveillance. It collects specimens for sequencing through the National SARS-CoV-2 Strain Surveillance program as well as data from commercial and academic laboratories under contract to state and local public health agencies. Nowcast is their model for reporting proportions of the variants by HHS region and week. CDC announced that delta became the dominant variant on July 7 and that the variant accounted for 83% of isolates by July 20. These findings corresponded to an alarming increase in the 7-day moving average for reported cases from 12,000 in late June to over 60,000 by July 27, 2021. This increase prompted CDC to issue new guidance on vaccinations and personal precautions for delta on that date. For the week of October 4, 2021, delta accounted for 99.2% of reported cases – a date which corresponds to the end of our sampling period. It was not overtaken by omicron as the dominant variant until the week of December 19, 2021. These data suggest that the great majority of cases presenting between July - September 2021 had delta. Our study showed that these patients had a worse prognosis compared to preceding cases and that the difference could not be explained by patient attributes or vaccination. A different approach was used by groups studying delta in England and Canada (9, 10). These groups studied patients with variants confirmed by viral genome sequencing and likewise found a poor prognosis for delta. Another difference between our study and theirs relates to the control of confounders. Poor outcomes can be attributed to the virulence of the variant, the degree to which the host response is compromised by pre-existing conditions, or both. Measures of virulence are valid to the extent that the latter is controlled. Although outcomes in their models were adjusted for demographic characteristics, one model

(9) did not include comorbidities while the other included the presence of “any documented major comorbidity” (10). Our novel approach to pre-existing conditions, vital signs, laboratory tests, and outpatient medications enable more rigorous control of cofounders than previously reported methods. In fact, we could not demonstrate that delta had a poorer outcome until these factors and vaccination status were controlled. This issue becomes more and more important as each surge culls the most vulnerable patients in a population – leading to a gradual change of patient characteristics in the susceptible population. Although they differ in design, all 3 studies confirm that the outcomes of delta infection are poorer and that the variant is more virulent than early variants.

Our programming has all the elements of a surveillance system for COVID outcomes. For example, surveys can be done over a moving time window in which the most recent quarter is compared to the prior 2 or 3. Results can be reported on a national level, by region, or for each facility. The system can track the outcomes of a dominant variant, monitor the transition from one variant to another, or generate aggregate results when multiple variants become established in the community. Newer anti-viral agents can be included in the model so that their effects on CFR can be adjusted for multiple patient characteristics, vaccination status, and the dominant variant. Because each patient has a predicted probability of death, an expected CFR can be derived for each facility. Differences between the observed and expected number of deaths should prompt an investigation into the cause. This investigation may be extended to include viral genome sequencing on stored samples. This process would add targeted testing on a national level to random sampling to identify variants of concern. The approach is practical and uses data already collected through electronic medical records. Finally, we have already run the routines repeatedly to resolve problems and identify the resources required to establish the workflow and framework.

Our validation studies show that our models can be used to predict COVID deaths even though not originally generated for that purpose. Given adequate resources, such an

assessment could be performed for every veteran before (s)he becomes ill. The risks can then be used to allocate scarce resources such as ICU beds, monoclonal antibody infusions, and/or anti-virals at the time of presentation. Prescreening is particularly important for Paxlovid® because its use is indicated for patients with mild to moderate symptoms but who are at risk for severe complications. The same information can also be used as a data-driven approach for counselling patients who are unvaccinated. Based upon our validation study, about 70% of veterans will have enough data to derive a predicted probability of death if they become infected. Of these patients, 1 of every 6 will belong to a group with a CFR of > 20%. We propose that members of this group be targeted for counseling if they are not vaccinated. Counseling would include a personalized assessment of risk, the patient's findings that contribute to that risk, and the degree to which the risk is mitigated by vaccination. This individualized approach is more likely to overcome vaccine hesitancy than a general discussion of risks and benefits which patients may not find relevant. The proposed strategies represent a personalized approach to COVID care.

Our models do not include the use of anti-virals, dexamethasone, anticoagulation, or monoclonal antibodies. The reason for such is that the most commonly used anti-viral agent – remdesivir – has little effect on patient mortality (11, 12). In addition, the effectiveness of dexamethasone treatment is not definitive, guidelines for anticoagulation therapies have not been fully formulated, and the use of monoclonal antibodies remains typically restricted. However, as effective anti-virals and other therapies are utilized on future cases, our models will be modified to evaluate their effects.

Although our findings show the effectiveness of vaccination, one cannot definitively prove that vaccination improved survival. For example, while we controlled for as many clinical variables as possible, there is no way of measuring all relevant patient attributes. Vaccination could be a marker for many traits that affect recovery from serious illness such as physical fitness, nutrition, medication compliance, preventive care and so forth. This possibility is

COVID VACCINATION AND CASE FATALITY RATE

19

suggested by the observation that vaccinated patients have a lower risk of death than unvaccinated persons even when COVID deaths are excluded (13).

Our conclusions are limited to patients with characteristics of the veteran population. Because our approach requires an extensive amount of baseline data, the results are also biased towards patients with chronic conditions that require periodic evaluation. Our methods represent a new approach to evaluating the effectiveness of interventions in observational studies. If validated by others for COVID and other diseases, findings presented here represent an alternative and perhaps more robust method for reconciling confounders.

COVID VACCINATION AND CASE FATALITY RATE

20

FIGURE 1: Case fatality rate (CFR) for delta infections by time from vaccination to diagnosis (in 4-week blocks). Cohort 1 was comprised of patients vaccinated 2-6 weeks prior to presentation while cohort 8 was vaccinated 30-34 weeks previously. The CFR for unvaccinated patients was 5.06%. Quadratic regression was used to examine the relationship between CFR and the midpoint of the sampling period for each cohort (midVxToDx). The expected CFR is given by the expression:

$$\text{Expected CFR} = 0.03747 - 0.00168 \times \text{midVxToDx} + 0.00007 \times \text{midVxToDx}^2$$

($R^2 = 0.9176$; $P = 0.0019$) where midVxToDx is expressed in weeks. This function reaches a minimal value for CFR of 2.73% at 12.1 weeks.

COVID VACCINATION AND CASE FATALITY RATE

21

FIGURE 2: Adjusted odds ratios for vaccination (AdjOR) by time from vaccination to diagnosis (in 4-week blocks). Cohorts are described in Figure 1. Note that the benefit of vaccination for preventing COVID death remains relatively stable across cohorts 3 to 8 (10-34 weeks).

COVID VACCINATION AND CASE FATALITY RATE

22

TABLE 1: CHARACTERISTICS OF NON-SURVIVORS AND SURVIVORS

Attribute	Non-Survivors	Survivors	P_Value
Age at diagnosis (years)	76.1 ± 11.2	57.6 ± 16.4	< 0.001
Male	97.5%	83.4%	<0.001
White	72.5%	63.1%	<0.001
Hispanic	7.0%	9.1%	<0.001
O2 supplementation	1.8%	0.7%	<0.001
Current smoker	8.9%	12.0%	<0.001
Charl2Yrs	3.23 ± 2.65	1.41 ± 2.00	<0.001*
CharlEver	4.99 ± 3.31	2.28 ± 2.77	<0.001*
Elix2Yrs	11.87 ± 12.75	4.77 ± 8.45	<0.001*
ElixEver	21.28 ± 16.62	9.47 ± 12.76	<0.001*
PDeathDx	0.139 ± 0.128	0.049 ± 0.064	<0.001*
PDeathLabs	0.136 ± 0.106	0.058 ± 0.065	<0.001*
AggRiskRx	-0.0854 ± 0.2720	-0.2025 ± 0.5424	<0.001*

* Mann-Whitney U-test

COVID VACCINATION AND CASE FATALITY RATE

23

TABLE 2: MAIN MULTIVARIATE MODEL

Variable	Odds Ratio	Std Error	Z_Score	P_Value	Lower CI	Higher CI
AgeAtDx	1.0656	0.0010	65.8100	0.0000	1.0636	1.0676
PDeathDx	5.6789	0.5630	17.5200	0.0000	4.6760	6.8970
PDeathLabs	15.5174	1.7617	24.1500	0.0000	12.4217	19.3845
VaccFlag	0.2802	0.0110	-32.5100	0.0000	0.2595	0.3026
Delta	1.8656	0.0494	23.5400	0.0000	1.7712	1.9651
CharlEver	1.0216	0.0060	3.6200	0.0000	1.0098	1.0334
Male	1.8282	0.1037	10.6400	0.0000	1.6359	2.0431
AggRiskRx	1.2671	0.0397	7.5700	0.0000	1.1918	1.3473
White	0.8599	0.0176	-7.3800	0.0000	0.8261	0.8951
ElixEver	1.0065	0.0009	6.9700	0.0000	1.0047	1.0083
Hispanic	1.2367	0.0433	6.0700	0.0000	1.1548	1.3245
Charl2Yrs	1.0323	0.0061	5.3500	0.0000	1.0203	1.0443
Veteran	2.9615	1.5124	2.1300	0.0340	1.0884	8.0579
Constant	0.0001	0.0000	-18.2200	0.0000	0.0000	0.0002

n = 239,393; ROC = 0.824

TABLE 3: MULTIVARIATE MODEL FOR EARLY VARIANTS

Variable	Odds Ratio	Std Error	Z_Score	P_Value	Lower CI	Higher CI
AgeAtDx	1.0681	0.0012	60.0600	0.0000	1.0658	1.0704
PDeathDx	5.7727	0.6256	16.1800	0.0000	4.6680	7.1388
PDeathLabs	14.6853	1.8320	21.5400	0.0000	11.5000	18.7530
CharlEver	1.0255	0.0067	3.8400	0.0000	1.0124	1.0388
VaccFlag	0.4039	0.0332	-11.0400	0.0000	0.3438	0.4744
Male	1.8551	0.1233	9.2900	0.0000	1.6285	2.1133
White	0.8241	0.0187	-8.5500	0.0000	0.7883	0.8614
AggRiskRx	1.3161	0.0485	7.4500	0.0000	1.2244	1.4147
Hispanic	1.2593	0.0488	5.9500	0.0000	1.1672	1.3585
ElixEver	1.0059	0.0010	5.7100	0.0000	1.0039	1.0080
Charl2Yrs	1.0250	0.0067	3.7600	0.0000	1.0119	1.0383
Constant	0.0002	0.0000	-87.3900	0.0000	0.0002	0.0003

n = 186,505; ROC = 0.826

TABLE 4: MULTIVARIATE MODEL FOR DELTA VARIANT

Variable	Odds Ratio	Std Error	Z_Score	P_Value	Lower CI	Higher CI
AgeAtDx	1.0570	0.0021	27.5400	0.0000	1.0529	1.0612
VaccFlag	0.2593	0.0119	-29.4700	0.0000	0.2370	0.2836
Charl2Yrs	1.0704	0.0119	6.1100	0.0000	1.0473	1.0941
PDeathLabs	20.0041	5.5087	10.8800	0.0000	11.6604	34.3181
PDeathDx	4.5774	1.1316	6.1500	0.0000	2.8196	7.4311

COVID VACCINATION AND CASE FATALITY RATE

24

Male	1.9115	0.2051	6.0400	0.0000	1.5490	2.3589
ElixEver	1.0094	0.0018	5.2800	0.0000	1.0059	1.0129
O2Supp	1.8408	0.2729	4.1200	0.0000	1.3766	2.4616
AggRiskRx	1.1373	0.0664	2.2000	0.0270	1.0144	1.2751
Constant	0.0007	0.0001	-46.2300	0.0000	0.0005	0.0010

n = 52,888; ROC = 0.818

TABLE 5: MULTIVARIATE MODEL FOR DERIVATION SET

Variable	Odds Ratio	Std Error	Z_Score	P_Value	Lower CI	Higher CI
AgeAtDx	1.0642	0.0013	50.1500	0.0000	1.0616	1.0668
PDeathLabs	15.9648	2.3263	19.0100	0.0000	11.9986	21.2421
PDeathDx	5.8042	0.7409	13.7800	0.0000	4.5195	7.4542
VaccFlag	0.2836	0.0143	-25.0400	0.0000	0.2570	0.3130
Delta	1.8565	0.0632	18.1900	0.0000	1.7368	1.9845
CharlEver	1.0176	0.0078	2.2800	0.0230	1.0024	1.0329
Male	1.9171	0.1414	8.8200	0.0000	1.6591	2.2153
ElixEver	1.0072	0.0012	5.9600	0.0000	1.0048	1.0096
AggRiskRx	1.2760	0.0515	6.0400	0.0000	1.1790	1.3811
White	0.8752	0.0234	-4.9900	0.0000	0.8305	0.9222
Hispanic	1.2690	0.0569	5.3200	0.0000	1.1623	1.3855
Charl2Yrs	1.0336	0.0079	4.3300	0.0000	1.0183	1.0492
NativeAm	1.5546	0.1721	3.9900	0.0000	1.2514	1.9312
Constant	0.0003	0.0000	-76.7700	0.0000	0.0002	0.0003

n = 144,427; ROC = 0.823

TABLE 6: MULTIVARIATE MODEL FOR THE VALIDATION SET

Variable	Odds Ratio	Std Error	Z_Score	P_Value	Lower CI	Higher CI
AgeAtDx	1.0678	0.0016	42.6100	0.0000	1.0646	1.0710
PDeathDx	5.5345	0.8713	10.8700	0.0000	4.0652	7.5349
PDeathLabs	14.4228	2.6136	14.7300	0.0000	10.1112	20.5730
VaccFlag	0.2750	0.0171	-20.7300	0.0000	0.2434	0.3107
Delta	1.8780	0.0793	14.9200	0.0000	1.7288	2.0401
CharlEver	1.0276	0.0095	2.9300	0.0030	1.0090	1.0464
Male	1.7797	0.1566	6.5500	0.0000	1.4978	2.1145
ElixEver	1.0056	0.0015	3.8000	0.0000	1.0027	1.0085
AggRiskRx	1.2492	0.0618	4.4900	0.0000	1.1337	1.3765
White	0.8618	0.0284	-4.5200	0.0000	0.8080	0.9193
Hispanic	1.1781	0.0660	2.9200	0.0030	1.0555	1.3149
Charl2Yrs	1.0308	0.0097	3.2200	0.0010	1.0119	1.0501
NativeAm	1.1253	0.1687	0.7900	0.4310	0.8387	1.5097
Constant	0.0002	0.0000	-63.5800	0.0000	0.0002	0.0003

n = 94,966; ROC = 0.826

TABLE 7: OBSERVED VERSUS PREDICTED DEATHS IN THE VALIDATION SET

[illegible]

REFERENCES

1. Cohn BA, Cirillo PM, Murphy CC, et al. SARS-CoV-2 vaccine protection and deaths among US veterans during 2021. *Science* 2021. DOI: 10.1126/science.abm0620.
2. Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. *Lancet*. 2021 Oct 16-22;398(10309):1407-16.
3. Yair Goldberg Y, Mandel M, Bar-On YM, et al. Waning immunity after the BNT162b2 vaccine in Israel. *N Engl J Med*. 2021 Dec 9; 385:e85.
4. Moghadas SM, Vilches TN, Zhang K, et al. The impact of vaccination on COVID-19 outbreaks in the United States. *medRxiv*. Preprint. 2020 Nov 30 [revised 2021 Jan 2]. DOI: 10.1101/2020.11.27.20240051.
5. Arbel R, Hammerman A, Sergienko R, et al. BNT162b2 vaccine booster and mortality due to Covid-19. *N Engl J Med*. 2021 Dec 23;385:2413-2420.
6. Murata GH, Murata AE, Campbell HM, McMahon BH, Mao JT. A novel method for handling pre-existing conditions in prediction models for COVID-19 death. *Medrxiv* 2022. doi: <https://doi.org/10.1101/2022.01.22.22269694>
7. Murata GH, Murata AE, Campbell HM, Wagner B, McMahon BH, Mao JT. Baseline metabolic profiling and risk of death from COVID-19. *Medrxiv* 2022. doi: <https://doi.org/10.1101/2022.01.22.22269691>
8. Hippisley-Cox J, Coupland CAC, Mehta N, et al. Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study. *BMJ* 2021;374:n2244.
9. Twohig KA, Nyberg T, Zaidi A, et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. *Lancet Infect Dis*. 2022 Jan;22(1):35-42. doi: 10.1016/S1473-3099(21)00475-8. Epub 2021 Aug 27.

COVID VACCINATION AND CASE FATALITY RATE

27

10. Fisman DN, Tuite AR. Evaluation of the relative virulence of novel SARS-CoV-2 variants: a retrospective cohort study in Ontario, Canada. CMAJ. 2021 October 25;193:E1619-25. doi: 10.1503/cmaj.211248.
11. Wilt TJ, Kaka AS, MacDonald R, et al. COVID-19: Remdesivir for Adults – A Living Review. Updated August 2021. Washington, DC: Evidence Synthesis Program, Health Services Research and Development Service, Office of Research and Development, Department of Veterans Affairs. VA ESP Project #09-009; Aug 2021.
12. Ohl M, Miller D, Lund B, et al. Association of remdesivir treatment with survival and length of hospital stay among US veterans hospitalized with COVID-19. JAMA Network Open. 2021 Jul 15, 2021;4(7):e2114741.
13. Xu S, Huang R, Sy LS, et al. COVID-19 vaccination and non-COVID-19 mortality risk – seven integrated health care organizations, United States, December 14, 2020 – July 31, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1520-24.